chronic heart failure
Conditions
Interventions
Trade Name: Omacor
Product Name: Omacor
Product Code: 1-21530
Pharmaceutical Form: Capsule, soft
INN or Proposed INN: eicosapentaeonic acid
Concentration unit: mg milligram(s)
Concentration type: equa
Sponsors
Dept. of Cardiology, Medical University of Vienna
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: chronic heart failure of non-ischemic origin Age =18 years NYHA functional class III-IV LVEF =65 years) yes F.1.3.1 Number of subjects for this age range
Exclusion criteria
Exclusion criteria: Current therapy with omacor or other fish oil products Known hypersensitivity to the study drug Ischemic cardiomyopathy Uncorrected significant valvular heart disase Heart failure due to congenital heart disease Restrictive cardiomyopathy Alcoholic heart disease Acute myocarditis continuous i.v. therapy for heart failure mechanical assist device Life expectancy <1 year due to non-cardiac causes Inability to perform bicycle testing Women of childbearing potential who do not practice a save contraception method Current participation in another intervention study. Previous participation in another study with an intervention within the last 3 months.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Main Objective: To investigate whether n3-fatty acids iimprove endothelial dysfunction in chronic heart failure.;Secondary Objective: To investigate whether n3-fatty acids have beneficial effects in chronic heart failure in terms of counteracting left ventricular remodelling, reducing ventricular wall stress, and improving exercise capacity.;Primary end point(s): Treatment-induced improvement in flow-mediated vasodilation as assessed by brachialis ultrasound | — |
Countries
Austria
Outcome results
None listed